Demeclocycline

Mechanism-of-action class: Protein Synthesis Inhibitors.

• Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated …ICD-10: H10.9

• This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the components of the product formulation.contraindicated

Therapy should be continued for at least 24 to 48 hours after symptoms and fever have subsided. Concomitant therapy: Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium and by iron-containing preparations. Foods and some dairy products also interfere with absorption. Oral forms of tetracycline should be given at least 1 hour before or 2 hours after meals. In patients with renal impairment: (see WARNINGS ). Tetracyclines should be used cautiously in patients with impaired renal function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses. In patients with liver impairment: Tetracyclines should be used cautiously in patients with impaired liver function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses. Administration of adequate amounts of fluid with the oral formulations of tetracyclines is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration (see ADVERSE REACTIONS ). Adults: Usual daily dose – Four divided doses of 150 mg each or two divided doses of 300 mg each. For pediatric patients above eight years of age: Usual daily dose, 7 to 13 mg per kg body weight per day, depending upon the severity of the disease, divided into two to four doses not to exceed adult dosage of 600 mg per day.

DEMECLOCYCLINE HCl, LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY, OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg/ every six hours. This reaction was shown to be reversible when the drug was discontinued. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. The anti-anabolic action of the tetracyclines may cause an increase in BUN.

The following reactions have been reported in patients receiving tetracyclines: Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, pancreatitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, increases in liver enzymes, and hepatic toxicity has been reported rarely. Rarely, hepatitis and liver failure have been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Instances of esophageal ulcerations have been reported in patients receiving oral tetracyclines. Most of the patients were reported to have taken the medication immediately before lying down (see DOSAGE AND ADMINISTRATION ). Skin: Maculopapular and erythematous rashes, erythema multiforme. Exfoliative dermatitis has been reported but is uncommon. Fixed drug eruptions and Stevens-Johnson syndrome have been reported rarely. Lesions occurring on the glans penis have caused balanitis. Pigmentation of the skin and mucous membranes has also been reported. Photosensitivity is discussed above (see WARNINGS ). Renal toxicity: Acute renal failure, rise in BUN has been reported and is apparently dose related, nephrogenic diabetes insipidus (see WARNINGS ). Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, anaphylactoid purpura, pericarditis exacerbation of systemic lupus erythematosus, lupus-like syndrome, pulmonary infiltrates with eosinophilia. Hematologic: Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported.

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Tetracyclines are not removed in significant quantities by hemodialysis or peritoneal dialysis.

• Feb 27, 2008ANDAANDA065425Amneal Pharm
• Aug 18, 2015ANDAANDA065447Epic Pharma Llc

1. 1Hyponatraemia3917%
2. 2Diarrhoea2511%
3. 3Asthenia229.8%
4. 4Oedema Peripheral167.1%
5. 5Dizziness156.7%
6. 6Fatigue156.7%
7. 7Nausea156.7%
8. 8Dehydration146.2%
9. 9Acute Kidney Injury135.8%
10. 10Pneumonia135.8%
11. 11Death125.3%
12. 12Malaise125.3%
13. 13Atrial Fibrillation114.9%
14. 14Constipation114.9%
15. 15Diabetes Insipidus114.9%

Recent PubMed references pinned to Demeclocycline as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Development and Reversal of Discolouration in Roots Filled with Ledermix or Doxymix Pastes Stored in the Dark for Three Months then Daylight for Twenty Four Months.
  European endodontic journal · 2022 · Athanassiadis B, Walsh LJ, Abbott PV, et al.
  PMID 36217644DOI 10.14744/eej.2022.07108
• Ledermix in children.
  British dental journal · 2021 · Al-Saffar H, Dadnam D
  PMID 33712760DOI 10.1038/s41415-021-2796-3
• Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes.
  Frontiers in immunology · 2020 · Sarkar S, Li Y, Mirzaei R, et al.
  PMID 32153581DOI 10.3389/fimmu.2020.00272
• TAR cloning and integrated overexpression of 6-demethylchlortetracycline biosynthetic gene cluster in Streptomyces aureofaciens.
  Acta biochimica et biophysica Sinica · 2017 · Wu N, Huang H, Min T, et al.
  PMID 29087452DOI 10.1093/abbs/gmx110
• Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
  Endocrine · 2017 · Tzoulis P, Carr H, Bagkeris E, et al.
  PMID 27837439DOI 10.1007/s12020-016-1161-9
• [Pregnancy and lactation period: Which antibiotic and rinsing solutions?].
  Swiss dental journal · 2016 · Fatori Popovic S, Lübbers HT, von Mandach U, et al.
  PMID 27377565DOI 10.61872/sdj-2016-06-04
• [Pregnancy and lactation period: Which antibiotic and rinsing solutions?].
  Swiss dental journal · 2016 · Fatori Popovic S, Lübbers HT, von Mandach von Mandach U, et al.
  PMID 27277144DOI 10.61872/sdj-2016-05-05
• Response to 'How we define hyponatremia?'.
  European journal of clinical investigation · 2015 · Grant P, Ayuk J, Bouloux PM, et al.
  PMID 26343423DOI 10.1111/eci.12515

The 6 most recently updated of 6 ClinicalTrials.gov registrations naming Demeclocycline as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Patients Response to Early Switch To Oral:Osteomyelitis Study
  Terminated · Early phase 1 · Interventional · 11 enrolled · Julio Ramirez
  NCT02099240updated 2021-04-06
• Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
  Completed · Phase 4 · Interventional · 6 enrolled · Amgen
  NCT02576652updated 2019-04-26
• The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone
  Terminated · Phase 2 · Interventional · 27 enrolled · University of Michigan
  NCT01279187updated 2018-02-07
• Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors
  Unknown · Phase 1 · Interventional · 40 enrolled · Massachusetts General Hospital
  NCT02740933updated 2016-04-15
• Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
  Completed · Phase 4 · Interventional · 69 enrolled · Eli Lilly and Company
  NCT01753856updated 2015-10-08
• S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307
  Withdrawn · Observational · 0 enrolled · SWOG Cancer Research Network
  NCT00873808updated 2013-04-10

Frequently asked questions

How does Demeclocycline work?

Mechanism-of-action class: Protein Synthesis Inhibitors.

What is Demeclocycline used for?

According to FDA labeling, Demeclocycline carries indications including: Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated …. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Demeclocycline?

Demeclocycline is classified as Tetracycline and derivatives, Tetracyclines, Tetracycline-class Antimicrobial, Protein Synthesis Inhibitors, Cell Membrane Alteration, Decreased Mitosis, Decreased Protein Synthesis.

What are the contraindications for Demeclocycline?

Demeclocycline labeling lists contraindications including: This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the components of the product formulation.. Always consult the full prescribing information and a clinician.